These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37366065)

  • 1. Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis.
    Farina N; Campochiaro C; Lescoat A; Benanti G; De Luca G; Khanna D; Dagna L; Matucci-Cerinic M
    Expert Rev Clin Immunol; 2023; 19(9):1131-1142. PubMed ID: 37366065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
    Lescoat A; Varga J; Matucci-Cerinic M; Khanna D
    Expert Opin Investig Drugs; 2021 Jun; 30(6):635-652. PubMed ID: 33909517
    [No Abstract]   [Full Text] [Related]  

  • 3. Emerging drugs and therapeutics for systemic sclerosis.
    Lee JJ; Pope JE
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in biological and targeted therapies for systemic sclerosis.
    Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D
    Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.
    Zhao M; Wu J; Wu H; Sawalha AH; Lu Q
    Clin Rev Allergy Immunol; 2022 Apr; 62(2):273-291. PubMed ID: 33449302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies.
    Asano Y; Varga J
    Semin Cell Dev Biol; 2020 May; 101():146-160. PubMed ID: 31859147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis.
    Ntelis K; Solomou EE; Sakkas L; Liossis SN; Daoussis D
    Semin Arthritis Rheum; 2017 Dec; 47(3):409-417. PubMed ID: 28602360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting vascular disease in systemic sclerosis.
    Kowal-Bielecka O
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):401-7. PubMed ID: 17214586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy of systemic sclerosis.
    Postlethwaite AE; Harris LJ; Raza SH; Kodura S; Akhigbe T
    Expert Opin Pharmacother; 2010 Apr; 11(5):789-806. PubMed ID: 20210685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
    Distler O; Cozzio A
    Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy.
    Henry TW; Mendoza FA; Jimenez SA
    Autoimmun Rev; 2019 Nov; 18(11):102396. PubMed ID: 31520794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contemporary management of systemic sclerosis.
    Eldoma M; Pope J
    Expert Rev Clin Immunol; 2018 Jul; 14(7):573-582. PubMed ID: 29874475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
    Hasegawa M; Takehara K
    Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the Notch pathway in the pathogenesis of systemic sclerosis: clinical implications.
    Seguro Paula F; Delgado Alves J
    Expert Rev Clin Immunol; 2021 Dec; 17(12):1257-1267. PubMed ID: 34719325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis.
    Del Papa N; Zaccara E
    Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):756-69. PubMed ID: 27107511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifibrotics in systemic sclerosis.
    Martin-Lopez M; Carreira PE
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101671. PubMed ID: 33839046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies.
    Fallet B; Walker UA
    Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1203-1218. PubMed ID: 33008265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis.
    Kawaguchi Y; Kuwana M
    Curr Opin Rheumatol; 2023 Nov; 35(6):309-316. PubMed ID: 37490353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.